Skip to main content

Advertisement

SpringerLink
Log in

Stroke in patients with systemic lupus erythematosus and antiphospholipid antibody syndrome

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Primary prevention of strokes in patients with antiphospholipid antibodies (APLs) with or without systemic lupus erythematosus (SLE) is not well known. The same applies to patients with SLE and valvular heart disease. The decision should be made on an individual basis until further studies become available. Special consideration for preventive antithrombotic treatment should be given to patients with persistent high titers of immunoglobulin G APLs, which require protein cofactor for detection, presence of lupus anticoagulant, or left-sided cardiac valve lesions. High-level oral anticoagulation with warfarin is still the preferred treatment for secondary prevention of strokes in patients with antiphospholipid antibody syndrome (APS) with or without SLE or with cardiac valvular lesions. Immunosuppression should only be used in patients with active SLE disease. There is no evidence so far to support its use in patients with primary APS. Advances in identifying unique APL features that are associated with increased risk for thrombosis will hopefully allow a more rational treatment for primary and secondary prevention of strokes in these patients in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Brey RL, Holliday SL, Saklad AR, et al.: Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002, 58:1214–1220. Overview of the different neuropsychiatric syndromes in patients with the diagnosis of lupus according to the American Rheumatism Association criteria.

    PubMed  CAS  Google Scholar 

  2. Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309–1311. The criteria for definitive APS is proposed by international experts in this subject.

    Article  PubMed  CAS  Google Scholar 

  3. Luong TH, Rand JH, Wu XX, et al.: Seasonal distribution of antiphospholipid antibodies. Stroke 2001, 32:1707–1711. First report of seasonal variation of the APLs in normal patients.

    PubMed  CAS  Google Scholar 

  4. Brey RL, Abbott RD, Curb JD, et al.: beta2-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction. The Honolulu Heart Program. Stroke 2001, 32:1701–1706. Prospective study showing an independent association between cofactor-dependent anticardiolipin antibodies with stroke and myocardial infarction.

    PubMed  CAS  Google Scholar 

  5. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. The Antiphospholipid Antibodies in Stroke Study Group [no authors listed]. Stroke 1990, 21:1268–1273.

  6. Brey RL, Chapman J, Levine SR, et al.: Stroke and the antiphospholipid syndrome: consensus meeting in Taormina 2002. Lupus 2003, 12:508–513. In-depth review of the evidence showing an association between APLs and stroke, as well as the current therapeutic controversies for this condition.

    Article  PubMed  CAS  Google Scholar 

  7. Hojnik M, George J, Ziporen L, Shoenfeld Y: Heart involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996, 93:1579–1587.

    Google Scholar 

  8. Johnson RT, Richardson EP: The neurological manifestations of systemic lupus erythematosus: a clinicalpathological study of 24 cases and review of the literature. Medicine 1968, 47:337–369.

    Article  PubMed  CAS  Google Scholar 

  9. Devinsky O, Petito CK, Aloso DR: Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988, 23:380–384.

    Article  PubMed  CAS  Google Scholar 

  10. Kitagawa Y, Gotoh F, Koto A, Okayasu H: Stroke in systemic lupus erythematosus. Stroke 1990, 21:1533–1539.

    PubMed  CAS  Google Scholar 

  11. Brey RL, Levine SR: Treatment of neurologic complications of antiphospholipid antibody syndrome. Lupus 1996, 5:473–476.

    Google Scholar 

  12. Khamashata MA, Cuadrado MJ, Mujic F, et al.: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995, 332:993–997.

    Article  Google Scholar 

  13. Fluture A, Chaudhari S, Frishman WH: Valvular heart disease and systemic lupus erythematosus: therapeutic implications. Heart Dis 2003, 5:349–353. Review of the therapeutic management of patients with lupus and valvular heart disease.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lahey Clinic, 41 Mall Road, 01805, Burlington, MA, USA

    Claudia J. Chaves MD

Authors
  1. Claudia J. Chaves MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaves, C.J. Stroke in patients with systemic lupus erythematosus and antiphospholipid antibody syndrome. Curr Treat Options Cardiovasc Med 6, 223–229 (2004). https://doi.org/10.1007/s11936-996-0017-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-996-0017-7

Keywords

Search

Navigation